Rivoceranib 200mg每日一次对CYP酶探针底物鸡尾酒药代动力学的影响:健康志愿者I期试验
该开放标签、固定序列、交叉设计I期药物相互作用试验在18名健康志愿者中评估了Rivoceranib 200mg每日一次多剂量给药对改良Cooperstown 5+1鸡尾酒中多种CYP酶底物单次给药药代动力学的影响。结果显示Rivoceranib可能显著抑制CYP2D6底物代谢,对CYP3A、CYP2C9和CYP2C19底物有弱抑制作用。
要点
- Rivoceranib 200mg每日一次可能显著抑制CYP2D6底物代谢,合用时需谨慎。
- 对CYP3A、CYP2C9和CYP2C19底物有弱抑制作用,建议密切监测底物相关不良反应。
- 无法避免与CYP2D6底物合用时,可能需要调整底物剂量。
核心结论
- Rivoceranib 200mg每日一次可能显著抑制CYP2D6底物代谢,合用时需谨慎并可能需要调整底物剂量。
- Rivoceranib对CYP3A、CYP2C9和CYP2C19底物代谢可能有弱抑制作用,建议密切监测底物相关不良反应。
研究设计与样本
- 开放标签、固定序列、交叉、药物相互作用I期试验,纳入18名健康志愿者。
- 第1天单次给予改良Cooperstown 5+1鸡尾酒,第11天给予Rivoceranib加鸡尾酒,第6-10天和第12-15天餐后单次给予Rivoceranib。
- 药代动力学血样采集至鸡尾酒给药后120小时,第21-25天进行安全性随访。
主要发现
- Rivoceranib 200mg每日一次使咖啡因AUC0-inf降低20%、Cmax降低7%。
- 使S-华法林AUC0-inf增加1.35倍、Cmax增加1.05倍。
- 使奥美拉唑AUC0-inf增加2.06倍、Cmax增加1.64倍。
- 使右美沙芬AUC0-inf增加2.67倍、Cmax增加1.9倍。
- 使咪达唑仑AUC0-inf增加1.44倍、Cmax增加1.15倍。
关键数值与推荐
- CYP1A2底物咖啡因200mg:AUC0-inf降低20%,Cmax降低7%。
- CYP2C9底物S-华法林10mg(联合维生素K 10mg):AUC0-inf增加1.35倍,Cmax增加1.05倍。
- CYP2C19底物奥美拉唑40mg:AUC0-inf增加2.06倍,Cmax增加1.64倍。
- CYP2D6底物右美沙芬30mg:AUC0-inf增加2.67倍,Cmax增加1.9倍。
- CYP3A4底物咪达唑仑2mg:AUC0-inf增加1.44倍,Cmax增加1.15倍。
临床怎么用
- 与CYP2D6底物药物合用时需谨慎,无法避免时应考虑调整CYP2D6底物剂量。
- 与CYP3A、CYP2C9、CYP2C19底物合用时建议密切监测底物相关不良反应,尤其当毒性对暴露增加敏感时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Rivoceranib, a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor with antitumor activity, is metabolized in the liver mostly by cytochrome P450 (CYP)3A4/5. In vitro studies suggest that rivoceranib at clinically relevant concentrations may inhibit metabolism of various CYP substrates. This study evaluated the effects of rivoceranib 200 mg once daily (QD) on the pharmacokinetics of various CYP substrates using the Cooperstown 5+1 cocktail. The dosing regimen of rivoceranib used in this study is similar to the proposed rivoceranib regimen (250 mg QD) in combination with camrelizumab for the treatment of patients with hepatocellular carcinoma. METHODS: This open-label, fixed-sequence, crossover, drug-drug interaction phase I study evaluated the impact of multiple oral doses of rivoceranib 200 mg QD on the single oral dose pharmacokinetics of CYP enzyme substrates administered in the modified Cooperstown 5+1 cocktail (caffeine 200 mg [CYP1A2], warfarin 10 mg [S-warfarin as CYP2C9 substrate] + vitamin K 10 mg, omeprazole 40 mg [CYP2C19], dextromethorphan 30 mg [CYP2D6], and midazolam 2 mg [CYP3A4]) in 18 healthy volunteers. After fasting, volunteers received a single dose of the Cooperstown 5+1 cocktail on day 1 and rivoceranib plus Cooperstown 5+1 cocktail on day 11. After completing a meal, volunteers received a single dose of rivoceranib on days 6-10 and 12-15. Blood samples for pharmcokinetic analyses of substrates were collected pre-dose and up to 120 h post-Cooperstown 5+1 cocktail dosing on days 1 and 11. Volunteers returned once between days 21 and 25 for safety follow-up. RESULTS: Rivoceranib 200 mg QD decreased the cumulative area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) for caffeine by 20% and maximum observed plasma concentration (Cmax) by 7%, increased S-warfarin AUC0-inf by 1.35-fold and Cmax by 1.05-fold, increased omeprazole AUC0-inf by 2.06-fold and Cmax by 1.64-fold, increased dextromethorphan AUC0-inf by 2.67-fold and Cmax by 1.9-fold, and increased midazolam AUC0-inf by 1.44-fold and Cmax by 1.15-fold. CONCLUSIONS: Rivoceranib 200 mg QD may substantially inhibit the metabolism of CYP2D6 substrates. Therefore, concomitant use of CYP2D6 substrate drugs with rivoceranib should be approached with caution, and dose adjustment of substrates of CYP2D6 may be necessary when co-administration cannot be avoided. Rivoceranib 200 mg QD may also exert weak inhibitory effects on the metabolism of CYP3A, CYP2C9, and CYP2C19 substrates. In such cases, close monitoring for substrate-related adverse reactions is recommended, particularly when toxicity is sensitive to increased exposures of these substrate drugs. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03561298.
引用
- Nguyen D, Wei XT, Meng X, et al. Effect of Rivoceranib 200 mg Once Daily on the Pharmacokinetics of a Cocktail Probe Substrate of Cytochrome P450 Enzymes: A Phase I Trial in Healthy Volunteers. Clin Pharmacokinet. 2026. PMID: 42667590. doi:10.1007/s40262-026-01686-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。